MX2023008773A - Composicion de vacuna para romper la autotolerancia. - Google Patents
Composicion de vacuna para romper la autotolerancia.Info
- Publication number
- MX2023008773A MX2023008773A MX2023008773A MX2023008773A MX2023008773A MX 2023008773 A MX2023008773 A MX 2023008773A MX 2023008773 A MX2023008773 A MX 2023008773A MX 2023008773 A MX2023008773 A MX 2023008773A MX 2023008773 A MX2023008773 A MX 2023008773A
- Authority
- MX
- Mexico
- Prior art keywords
- self
- vaccine composition
- polyprotein
- host
- tolerance
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 108010076039 Polyproteins Proteins 0.000 abstract 4
- 230000002265 prevention Effects 0.000 abstract 2
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001823 pruritic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una composición de vacuna para romper la autotolerancia contra una autoproteína de un huésped, en particular para romper la autotolerancia contra citocinas endógenas en un huésped animal. La composición de vacuna de la invención contiene una poliproteína, un ADN que codifica la poliproteína y/o un ARN que codifica la poliproteína y uno o más oligonucleótidos inmunoestimuladores. La poliproteína comprende al menos dos segmentos de autoproteína del huésped y uno o más epítopos de células T de origen no huésped entre y/o adyacentes a los al menos dos segmentos de autoproteína. La presente invención se refiere además al uso de la composición de vacuna para la prevención y/o tratamiento de enfermedades, incluida la prevención y/o tratamiento de una afección pruriginosa y/o alérgica. En otro aspecto, la presente invención proporciona un método para detectar la presencia de autoanticuerpos contra autoproteínas que pueden generarse con la composición de la vacuna de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21154244 | 2021-01-29 | ||
| PCT/EP2022/052153 WO2022162204A1 (en) | 2021-01-29 | 2022-01-29 | Vaccine composition for breaking self-tolerance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008773A true MX2023008773A (es) | 2023-08-08 |
Family
ID=74418234
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008774A MX2023008774A (es) | 2021-01-29 | 2022-01-29 | Composicion de vacuna para romper la autotolerancia. |
| MX2023008773A MX2023008773A (es) | 2021-01-29 | 2022-01-29 | Composicion de vacuna para romper la autotolerancia. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008774A MX2023008774A (es) | 2021-01-29 | 2022-01-29 | Composicion de vacuna para romper la autotolerancia. |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4284830A1 (es) |
| JP (2) | JP2024504194A (es) |
| KR (2) | KR20230136172A (es) |
| CN (2) | CN117083296A (es) |
| AU (2) | AU2022215119A1 (es) |
| CA (2) | CA3209842A1 (es) |
| MX (2) | MX2023008774A (es) |
| WO (2) | WO2022162204A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024057096A1 (en) * | 2022-09-14 | 2024-03-21 | Ceva Sante Animale | Treatment of atopic dermatitis using self-replicating rna expressing il-31 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
| JP2006501249A (ja) * | 2002-08-30 | 2006-01-12 | グラクソ グループ リミテッド | ワクチン |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2019086694A1 (en) * | 2017-11-06 | 2019-05-09 | Geert Mudde | Il31 antigen and vaccine |
| EP3765069A1 (en) * | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Peptide vaccines against interleukin-31 |
-
2022
- 2022-01-29 JP JP2023545831A patent/JP2024504194A/ja active Pending
- 2022-01-29 KR KR1020237028779A patent/KR20230136172A/ko unknown
- 2022-01-29 WO PCT/EP2022/052153 patent/WO2022162204A1/en active Application Filing
- 2022-01-29 WO PCT/EP2022/052154 patent/WO2022162205A1/en active Application Filing
- 2022-01-29 EP EP22703598.7A patent/EP4284830A1/en active Pending
- 2022-01-29 MX MX2023008774A patent/MX2023008774A/es unknown
- 2022-01-29 MX MX2023008773A patent/MX2023008773A/es unknown
- 2022-01-29 AU AU2022215119A patent/AU2022215119A1/en active Pending
- 2022-01-29 CA CA3209842A patent/CA3209842A1/en active Pending
- 2022-01-29 AU AU2022212600A patent/AU2022212600A1/en active Pending
- 2022-01-29 KR KR1020237028778A patent/KR20230137385A/ko unknown
- 2022-01-29 CN CN202280026257.7A patent/CN117083296A/zh active Pending
- 2022-01-29 CN CN202280026259.6A patent/CN117222664A/zh active Pending
- 2022-01-29 CA CA3209969A patent/CA3209969A1/en active Pending
- 2022-01-29 JP JP2023545830A patent/JP2024505525A/ja active Pending
- 2022-01-29 EP EP22703599.5A patent/EP4284831A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230136172A (ko) | 2023-09-26 |
| EP4284831A1 (en) | 2023-12-06 |
| WO2022162204A1 (en) | 2022-08-04 |
| EP4284830A1 (en) | 2023-12-06 |
| CN117222664A (zh) | 2023-12-12 |
| WO2022162205A1 (en) | 2022-08-04 |
| JP2024505525A (ja) | 2024-02-06 |
| KR20230137385A (ko) | 2023-10-04 |
| JP2024504194A (ja) | 2024-01-30 |
| AU2022215119A1 (en) | 2023-08-17 |
| MX2023008774A (es) | 2023-08-08 |
| CA3209842A1 (en) | 2022-08-04 |
| AU2022212600A1 (en) | 2023-08-17 |
| CN117083296A (zh) | 2023-11-17 |
| CA3209969A1 (en) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6484558B2 (ja) | 癌ワクチンの組み合せ物 | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| GB2467685A (en) | Risk scoring system for the prevention of malware | |
| ITMI20021527A1 (it) | Anticorpi anti componente c5 del complemento e loro uso | |
| FR2822164B1 (fr) | Polypeptides derives des arn polymerases, et leurs utilisations | |
| ATE503770T1 (de) | Humane monoklonale antikörper gegen hendra- und nipah-viren | |
| SI1730315T1 (sl) | Polimorfizmi v genu NOD2/CARD15 | |
| MX2023008773A (es) | Composicion de vacuna para romper la autotolerancia. | |
| EA201390740A1 (ru) | Способ лечения с использованием ингибитора braf | |
| BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
| BRPI0512421A (pt) | recombinantes de avipox expressando genes do vìrus da doença febre aftosa | |
| MX2022007120A (es) | Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso. | |
| MX2022014387A (es) | Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva). | |
| MX2020013229A (es) | Endonucleasas cpf1 mutantes. | |
| PH12019500927A1 (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| BR112021026382A2 (pt) | Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer | |
| ATE332979T1 (de) | Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs | |
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| Erfan et al. | Downregulation of calcineurin gene is associated with Glucantime® resiatance in Leishmania infantum | |
| HUP9903299A2 (hu) | FAS-antigén elleni antitestek | |
| MX2022016061A (es) | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. | |
| WO2018202931A3 (es) | Método de diagnóstico de placas ateroscleróticas inestables | |
| ATE403005T1 (de) | Rekombinantes mva und verfahren zur erzeugung davon | |
| BR112022000020A2 (pt) | Antígenos de câncer inovadores e métodos | |
| JP2015513901A5 (es) |